Novel oral anticoagulants and their role in clinical practice

Pharmacotherapy

Volumn 31, Issue 12, 2011, Pages 1175-1191

  Wittkowsky, Ann K ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Anticoagulation; Apixaban; Atrial fibrillation; Dabigatran; Rivaroxaban; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; APIXABAN; CLARITHROMYCIN; CYCLOSPORIN; DABIGATRAN ETEXILATE; EDOXABAN; ENOXAPARIN; ERYTHROMYCIN; HEPARIN; ITRACONAZOLE; KETOCONAZOLE; LIXIANA; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; QUINIDINE; RIFAMPICIN; RITONAVIR; RIVAROXABAN; TACROLIMUS; UNCLASSIFIED DRUG; VERAPAMIL; WARFARIN;

ANTICOAGULANT THERAPY; AREA UNDER THE CURVE; BLEEDING; BRAIN HEMORRHAGE; CLINICAL PRACTICE; DOSE RESPONSE; DRUG APPROVAL; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG USE; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HUMAN; KIDNEY FAILURE; REVIEW; STROKE; THROMBOSIS PREVENTION; TIME TO MAXIMUM PLASMA CONCENTRATION; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; DRUG APPROVAL; DRUG DESIGN; FACTOR XA; HUMANS; PROTHROMBIN; STROKE; UNITED STATES; VENOUS THROMBOEMBOLISM; WARFARIN;

EID: 83055178394     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.31.12.1175     Document Type: Review

References (70)

1. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133(6 suppl):S381-453.
2. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133(6 suppl):S454-545.
3. Salem DN, O'Gara PT, Madias C, Pauker SG. Valvular and structural heart disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133(6 suppl):S593-629.
4. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy for atrial fibrillation: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133(6 suppl):S546-92.
5. Shappert SM, Rechtsteiner EA. Ambulatory medical care utilization estimates for 2007. National Center for Health Statistics, national ambulatory medical care survey. Available from http://www.cdc.gov/nchs/data/series/sr-13/ sr13-169.pdf. Accessed June 10, 2011.
6. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133(6 suppl):S160-98.
7. Bloomfield HE, Krause A, Greer N, et al. Meta-analysis: effect of patient self-testing and self-management of long-term anticoagulation on major clinical outcomes. Ann Intern Med 2011;154:472-82.
8. Shehab N, Sperling LS, Kegler SR, Budnitz DS. National estimates of emergency department visits for hemorrhage-related adverse events from clopidogrel plus aspirin and from warfarin. Arch Intern Med 2010;170:1926-33.
9. Schulman S, Anderson DR, Bungard TJ, et al. Direct and indirect costs of management of long-term warfarin therapy in Canada. J Thromb Haemost 2010;8:2192-200.
10. Ogata K, Mendell-Harary J, Tachibana M, et al. Clinical safety, tolerability, pharmacokinetics and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 2010;50:743-53.
11. Raghavan N, Frost CE, Yu Z, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Disp 2009;37:74-81.
12. Erikkson BI, Quinland DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinetics 2009;38:1-22.
13. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinetics 2008;47:285-95. (Pubitemid 351508116)
14. Johansson S, Cullberg M, Erikkson UG, et al. Single-dose pharmacokinetics, pharmacodynamics and safety of AZD0837, a novel oral direct thrombin inhibitor in young healthy male subjects. Int J Clin Pharmacol Ther 2011;49:258-67.
15. Wilke T, Muller S. Nonadherence to outpatient thromboprophylaxis after major orthopedic surgery:a systematic review. Expert Rev Pharmacoecon Outcomes Res 2010;10:691-700.
16. Erikkson B, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for the prevention of venous thromboembolism after total hip replacement: a randomized, double-blind non-inferiority trial. Lancet 2007;370:949-56. (Pubitemid 47393577)
17. Erikkson DI, Dahl OE, Huo MH, et al., for the RE-NOVATE II Study Group. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II): a randomized double-blind non-inferiority trial. Thromb Haemost 2011;105:721-9.
18. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. New Engl J Med 2008;358:2765-75. (Pubitemid 351930851)
19. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008;372:31-9.
20. Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM, for the ADVANCE 3 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010;363:2487-98.
21. Fuji T, Fujita S, Tachibana S, et al. Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-5 trial [abstract]. Blood 2010; 116:abstract 3320.
22. Dahl OE, Quinlan DJ, Bergqvist D, Eikelboom JW. A critical appraisal of bleeding events reported in venous thromboembolism prevention trials of patients undergoing hip and knee arthroplasty. J Thromb Haemost 2010;8:1966-75.
23. Ginsberg JS, Davidson BL, Comp PC, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009;24:1-9.
24. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007;5:2178-85. (Pubitemid 47617868)
25. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban vs enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2009;358:2776-86. (Pubitemid 351930852)
26. Turpie AGG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee replacement arthroplasty (RECORD 4): a randomized trial. Lancet 2009;373:1673-80.
27. Lassen MR, Raskob GE, Gallus A, et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009;361:594-604.
28. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P, for the ADVANCE 2 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE 2): a randomized double-blind trial. Lancet 2010;375:807-15.
29. Fui T. Edoxaban versus enoxaparin for thromboprophylaxis after total knee replacement (STARS E-3) [abstract OC297]. Presented at the International Congress of Thrombosis, Milan, Italy, July 6-9, 2010.
30. McCullagh L, Tilson L, Walsh C, Barry M. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the Irish healthcare setting. Pharmacoeconomics 2009;27:829-46.
31. Eikelboom JW, Karthikeyan G, Fagel H, Hirsh J. American Association of Orthopedic Surgeons and American College of Chest Physicians guidelines for venous thromboembolism prevention in hip and knee arthroplasty differ: what are the implications for clinicians and patients? Chest 2009;135:513-20.
32. Dobesh P. The importance of appropriate prophylaxis for the prevention of venous thromboembolism in at-risk medical patients. Int J Clin Practice 2010;64:1554-62.
33. Hull RD, Schellong SM, Tapson VF, et al. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med 2010;153:8-18.
34. Cohen AT, for the MAGELLAN Steering Committee and Investigators. Rivaroxaban compared with enoxaparin for the prevention of venous thromboembolism in acutely ill medical patients [abstract 3015-5]. Presented at the annual meeting of the American College of Cardiology, New Orleans, LA, April 5, 2011.
35. Schulman S, Kearon C, Kakkar AK, et al., for the RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342-52.
36. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499-510.
37. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. Circulation 2006;114:257-354.
38. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention - the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA 2001;285:2370-5. (Pubitemid 32424106)
39. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the national registry of atrial fibrillation. JAMA 2001;285:2864-70. (Pubitemid 32537350)
40. Connelly SJ, Ezekowitz MD, Yusuf S, et al., for the RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
41. Patel MR, Mahaffey KW, Garg J, et al., for the ROCKET AF Steering Committee and Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91.
42. Connelly SJ, Eikenbloom J, Joyner C, et al., for the AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806-17.
43. Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92.
44. Connelly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L. Newly identified events in the RE-LY trial. N Engl J Med 2010;363:1875-6.
45. Beasley BN, Unger EF, Temple R. Anticoagulant options: why the FDA approved a higher but not a lower dose of dabigatran. N Engl J Med 2011;364:1788-90.
46. Diener HC, Connolly SJ, Ezekowitz MD, et al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischemic attack or stroke: a subgroup analysis of the RELY trial. Lancet Neurol 2010;9:1157-63. (Erratum in Lancet Neurol 2011;10:27.)
47. Ezekowitz MD, Wallentin L, Connolly SJ, et al. Dabigatran and warfarin in vitamin K antagonist naive and experienced cohorts with atrial fibrillation. Circulation 2010;122:2246-53.
48. Nagarakanti R, Ezekowitz MD, Oldgren J, et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation 2011;123:131-6.
49. Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010;376:975-83.
50. Eikelboom JW, Wallentin L, Connelly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis from the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011;123:2363-72.
51. Gulseth MP, Wittkowsky AK, Fanikos J, Spinler SA, Dager WE, Nutescu EA. Dabigatran etexilate in clinical practice: confronting challenges to improve safety and effectiveness. Pharmacotherapy 2011;31:1234-52.
52. Van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate: a novel, reversible oral direct thrombin inhibitor - interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010;103:1116-27.
53. Samama MM, Martinoli JL, LeFlem L, et al. Assessment of laboratory assays to measure rivaroxaban, an oral direct factor Xa inhibitor. Thromb Haemost 2010;103:815-25.
54. Wong PC, Crain EJ, Xin B, et al. Apixaban, an oral direct and highly selective factor Xa inhibitor: in vitro antithrombotic and antihemostatic studies. J Thromb Haemost 2008;6:820-9. (Pubitemid 351524543)
55. Bounameaux H, Reber G. New oral antithrombotics: a need for laboratory monitoring. Against. J Thromb Haemost 2010;8:627-30.
56. Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions with warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis 2011;31:326-43.
57. DuBuske LM. The role of p-glycoprotein and organic anion-transporting polypeptides in drug interactions. Drug Saf 2005;28:789-801. (Pubitemid 41428552)
58. U.S. Food and Drug Administration. Briefing information for the September 20, 2010, meeting of the cardiovascular and renal drugs advisory committee. Available from http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/ UCM247244.pdf. Accessed July 8, 2011.
59. U.S. Food and Drug Administration. Product labeling for Pradaxa. Available from http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/ 022512s004lbl.pdf. Accessed July 8, 2011.
60. Health Canada. Summary basis of decision for Pradaxa. Available from http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/phase1-decision/drug-med/ sbd-smd-2008-pradax-114887-eng.php. Accessed July 8, 2011.
61. European Medicines Agency. European product assessment report for Pradaxa. Available from http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR---Product-Information/human/000829/WC500041059.pdf. Accessed July 8, 2011.
62. European Medicines Agency, Committee for Medicinal Products for Human Use. Summary of opinion (post-authorisation) for Pradaxa. Available from http://www.ema.europa.eu/docs/en-GB/document-library/Summary-of-opinion/human/ 000829/WC500105283.pdf. Accessed July 8, 2011.
63. Kivisto KT, Neimi M, Fromm MF. Functional interaction of intestinal CYP3A4 and p-glycoprotein. Fundam Clin Pharmacol 2004;18:621-6. (Pubitemid 39564261)
64. European Medicines Agency, Committee for Medicinal Products for Human Use. Assessment report for Xarelto. Available from http://www.ema.europa.eu/ docs/en-GB/document-library/EPAR---Public-assessment-report/human/000944/ WC500057122.pdf. Accessed July 8, 2011.
65. Euroopean Medicines Agency. European public assessment report for Xarelto. Available from http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR---Product-Information/human/000944/WC500057108.pdf. Accessed July 8, 2011.
66. Health Canada, Summary basis of decision for Xarelto. Available from http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/phase1-decision/drug-med/ sbd-smd-2009-xarelto-119111-eng.php. Accessed July 8, 2011.
67. U.S. Food and Drug Administration. Product labelling for Xarelto. Available from http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/ 022406s000lbl.pdf. Accessed July 8, 2011.
68. Limdi NA, Limdi MA, Cavallari L, et al. Warfarin dosing in patients with impaired kidney function. Am J Kidney Dis 2010;56:823-31.
69. Limdi NA, Beasley TM, Baird MF, et al. Kidney function influences warfarin responsiveness and hemorrhagic complications, J Am Soc Nephrol 2009;20:912-21.
70. Dreisbach AW, Japa S, Gebrekal AB, et al. Cytochrome P450 2C9 activity in end-stage renal disease. Clin Pharmacol Ther 2003;73:475-7. (Pubitemid 36549832)